ECP drivers and new wearer attitudes on 1-day silicone hydrogel lenses in Italy

ECP drivers and new wearer attitudes on 1-day silicone hydrogel lenses in Italy


Gary Orsborn OD MS FAAO FBCLA
Fabio Carta Dip. Optom MBCLA 
Dan Comoroda BA 
Caroline McGachen BA (Hons)


Purpose: An online survey was conducted with ECPs and new 1DSiHy wearers in Italy [February/March 2020] by Cello Health Insight, an independent market research agency. ECPs were actively prescribing CLs, had 3-35 years of CL experience, and were fitting >25 people/month (including >1 new 1DSiHy). New wearers were adults fit within the last 18 months.

Method: 50 ECPs fitted on average 31 new patients/month (14 1DSiHy). 100 new wearers were surveyed - mean age 36 years, 56% female, wore CLs 5 days/week and 9 hours/day. Key factors in influencing ECP decisions to recommend a 1DSiHy were “end of day comfort” (48%), “ability to wear for longer hours during day” (42%), “oxygen permeability” (40%) and “lower risk hypoxia-related eye problems” (40%). 78% ECPs believe it important to discuss high oxygen material options with patients. Key factors for new wearers deciding which lenses to wear were all day comfort (71%) and healthy for their eyes (61%). When ECPs identify patient-based factors leading them to recommend a SiHy material rather than a hydrogel, health consciousness was the most differentiating (+28% over hydrogel, p<0.01) followed by younger age (+16%, p<0.10). 48% ECPs report encountering objections about 1DSiHy cost, which was the primary patient concern. New wearers agree they are willing to pay more for a lens if it’s the healthiest (82%) or the most comfortable (75%) option.

Results: These insights highlight factors that help Italian ECPs recommending 1DSiHy CLs to new wearers. They tend to fit health-conscious patients and educate patients on comfort along with health reasons and oxygen permeability, and can use these to help overcome potential objections, particularly related to cost.

Conclusions: Dr. Gary Orsborn is Vice President, Global Professional, Medical & Clinical Affairs at CooperVision. He is responsible for the development, direction and management of the company’s professional, medical and clinical affairs strategies worldwide. Dr. Orsborn received his Doctor of Optometry degree and a Master of Science in Physiological Optics from The Ohio State University College of Optometry. He is a fellow of both the American Academy of Optometry and of the British Contact Lens Association, and a member of the American Optometric Association and the Association of Research and Vision in Ophthalmology.

1st Author Biography: Dr. Gary Orsborn is Vice President, Global Professional & Clinical Affairs at CooperVision. He is responsible for the development and management of the company’s professional and clinical affairs strategy worldwide. Dr. Orsborn received his Doctor of Optometry degree and a Master of Science in Physiological Optics from The Ohio State University College of Optometry. He is a fellow of both the American Academy of Optometry and of the British Contact Lens Association, and a member of the American Optometric Association and the Association of Research and Vision in Ophthalmology.

*Data correct at the time of submission to BCLA by NCC.